Navigation Links
Novel experiment documents evolution of genome in near-real time

A team led by bioengineering researchers at UC San Diego report in the November issue of Nature Genetics rapid evolutionary changes in a bacterial genome, observed in near-real time over a few days. Scientists have previously published static "snapshots" of the genome sequences of more than 100 bacterial species, from the harmless to those that cause plague, but this new report shows how these genomes are moving targets.

"Paleontologists look at the fossil record to study how evolution of dinosaurs and other animals occurred over millions of years, but in the case of the E. coli bacterium, new technology has given us the ability to observe evolution as it is occurring over a matter of days," said Bernhard Ø. Palsson, the senior author of the study and professor of bioengineering at UCSD. "The published genomic sequences of bacteria are like a fossil record and our experiments confirm that these genomes can change quickly as bacteria adapt to new conditions."

Because of past technical limitations, biologists have historically made inferences about rapid bacterial evolution by carefully observing changes in a handful of genes at a time or by monitoring the visible characteristics, or phenotypes, as the organisms adapt. Palsson's team used comparative genome sequencing technology developed by NimbleGen Systems Inc., a Madison, WI-based biotech firm, to identify changes that occurred during the experiment in the bacterium's complete set of genes.

In a paper scheduled for online publication Nov. 5 on Nature Genetics's Website, the researchers report that they grew E. coli in an environment that favored the emergence of mutants: the organism was fed a poorly metabolized carbon and energy source called glycerol. The researchers removed samples of cells from the culture and sequenced their entire genomes as a way to find mutations that enabled faster growth.

After six days of growth, mutations appeared in the gene for an enzyme that initia
'"/>

Source:University of California - San Diego


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Novel live reporting system to track cells
11. Field of beams - Novel system uses polarized light pulses to reveal crop health

Post Your Comments:
(Date:11/5/2009)...ty have developed synthetic molecules capable of e...-infected cells, as well as to prostate cancer cel...al of the American Chemical Society , could lead t... , The molecules called "antibody-recruiting m...iting molecule targeting prostate cancer" (ARM-P) ...
(Date:11/4/2009)...g Beach and Riverside are responsible for a signif...and the true impact of air pollution and ship emis...d, according to researchers at the University of S...pears in an online edition of the American Journa...f all childhood asthma cases in Long Beach and six...
(Date:11/4/2009)...eived more than $10 million in research grants fro...mulus program, bringing thetotal amount of stimulu...n. Thirty-three projects achieved stimulus fundin... , "The university has thoughtfully undertaken a... excellence to federal agency priorities. Through...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2USC study finds big air pollution impacts on local communities 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Zimmer Holdings to Present at Upcoming Investor Conferences 55934 1DIA Conference to Explore The Science and Scope of Personalized Medicine 55930 1DIA Conference to Explore The Science and Scope of Personalized Medicine 55930 2U S Labor Department announces dates for 4th annual Drug Free Work Week 55926 1U S Labor Department announces dates for 4th annual Drug Free Work Week 55926 2
...nced Identification Systems/Commerc... 28 /PRNewswire-FirstCall/-- Atmel (Nasdaq:,ATML),...ns, announced today,that Kerry Maletsky, Business ...nt "Secure Biometric Co-processor: Solving the Net...on Systems/Commercial Biometrics,Conference in Was...
...MEA spurs IdentiPHI,s company ...tiPHI, Inc., an innovative,leader in enterprise se...sion with the opening of an office in Paris to add...identity and authentication (access,management) pr...ope will enable us to more closely serve our,growi...
...cans are an increasingly used X-ray-based tool for...r organ or tissue. The value of CT scanning to dia...undisputed. But are these scans being used too fre... health consequences of having too many CT scans o... 2007 article in The New England Journal of Medici...
Other Biology News:Atmel's Biometric Co-processor Solution Featured at AIS/CBX 2IdentiPHI Opens Paris Office to Boost European Sales and Support 2Columbia researchers: Growth of CT scan use may lead to significant public health problem 2Columbia researchers: Growth of CT scan use may lead to significant public health problem 3
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Personali... to take place on February 22-24, 2010 in Philadel...ence we will highlight key issues in forming partn...r experiences. , Minneapo... Arrowhead’s 2010 Personalized Medicine Par...
(Date:11/5/2009)... Nov. 5 DSM Pharmaceutical Product... alliance with Galenix, Saint Jean D,Illac, France... manufacturing partner for Galenix commercial prod... collaborate on business development opportunities...based on the strength of Galenix in drug product d...
(Date:11/5/2009)... 5 Transgenomic, Inc. (O... results for the quarter ended September 30, 2009....the tables that follow. ,, Third Quarter 2009 ... or $0.01 per share for the third quarter of 2009 ... share for the third quarter of 2008. ,, Net s...
(Date:11/5/2009)...vember 5, 2009 Senomyx, ...proprietary taste receptor-based technologies to d...erage, and ingredient supply industries, today pro...sults for the third quarter ended September 30, 20...ter of 2009, compared to $4.0 million for the thir...
Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...lix BioPharma Corp. (TSX, FSE: "HBP") today announ...scal 2009, ended January 31, 2009. , , RECENT H...-F registration statement with the U.S. Securities... March 12, 2009 , , , , , , Helix...European Phase II pharmacokinetic study in human s...
... Protocol Driven Healthcare , Inc. (PDHI) now of...(HRA), the ConXus(R) Profile. The shorter format f...racy and reduces processing costs of paper assessm..., longer adult HRA, but joins PDHI,s suite of Con...students, children, and Spanish-speaking adults. ...
...nership Will Increase Productivity to Meet Growing... Indonesia (PRWEB) March 16, 2009 -- DuPont and ...oday announced an agreement that grants DuPont bus...ialize ICRR rice hybrids in Asia. , , , , ,Rice is... of the world,s population. The growing populatio...
Other Biology Technology:Helix BioPharma Announces Q2 2009 Financial Results 2Helix BioPharma Announces Q2 2009 Financial Results 3Helix BioPharma Announces Q2 2009 Financial Results 4Helix BioPharma Announces Q2 2009 Financial Results 5Helix BioPharma Announces Q2 2009 Financial Results 6Helix BioPharma Announces Q2 2009 Financial Results 7Helix BioPharma Announces Q2 2009 Financial Results 8Helix BioPharma Announces Q2 2009 Financial Results 9Helix BioPharma Announces Q2 2009 Financial Results 10Helix BioPharma Announces Q2 2009 Financial Results 11Helix BioPharma Announces Q2 2009 Financial Results 12PDHI Launches Short Form of Its ConXus Profile Health Assessment 2DuPont Partners with Indonesian Center for Rice Research to Advance Hybrid Rice 2DuPont Partners with Indonesian Center for Rice Research to Advance Hybrid Rice 3
Mouse Anti-IFN-alpha2 Monoclonal Antibody, Fluorescein isothiocyanate (FITC) Conjugated, Clone 225.C from eBioscience
Mouse Anti-alpha Sodium Potassium ATPase Monoclonal Antibody, Unconjugated, Clone M7-PB-E9 from Abcam
Rabbit Anti-Human SP2 Polyclonal Antibody, Unconjugated from Atlas Antibodies
Rabbit Anti-Asparagine synthetase Monoclonal Antibody, Unconjugated, Clone EP282Y from Abcam
Biology Products: